EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH
71% of pegcetacoplan-treated patients achieved LDH normalization vs. 15% of eculizumab-treated patients 73% of pegcetacoplan-treated patients achieved a clinically meaningful improvement in FACIT-fatigue score vs.
NodThera Announces Close of $55 Million Series B Financing
Financing round led by Novo Ventures and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital,
Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Submission of New Drug Application (NDA) planned for second half of 2020 following successful pre-NDA meeting with FDA WALTHAM, Mass., May 21, 2020 –
Apellis Reports Analysis from Phase 1b Geographic Atrophy Study
No cases of inflammation observed after 12 months with Phase 3 formulation of pegcetacoplan in patients with advanced geographic atrophy (GA) Decrease in mean lesion
Encouraging Interim Data from a Phase 1 Clinical Study Evaluating MOv18 IgE in Cancer Patients with Advanced Solid Tumours Presented at the AACR Virtual Annual Meeting
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Results support, for the first time, the safety and potential efficacy of an
Interim Phase 1 Data Evaluating MOv18 IgE, an Anti-folate Receptor Alpha IgE antibody, in Cancer Patients with Advanced Solid Tumours to be Presented at the AACR Virtual Annual Meeting I
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer London,
Epsilogen Licences MOv18 IgE, an Anti-folate Receptor Alpha IgE Antibody from King’s College London
MOv18 IgE is currently in phase 1 clinical trial in cancer patients with advanced solid tumours Folate receptor alpha most commonly overexpressed on tumour cells
Eternygen Presents Data Demonstrating INDY Inhibition as Novel Therapeutic Option in NASH
Study to be presented at 3rd Global NASH Congress in London, U.K., February 10, 11 Data show, for the first time, that INDY inhibition attenuates